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Abstract Given the severity of the SARS-CoV-2 pandemic, a major challenge is to rapidly repurpose
existing approved drugs for clinical interventions. While a number of data-driven and experimental
approaches have been suggested in the context of drug repurposing, a platform that systematically
integrates available transcriptomic, proteomic and structural data is missing. More importantly, given
that SARS-CoV-2 pathogenicity is highly age-dependent, it is critical to integrate aging signatures into
drug discovery platforms. We here take advantage of large-scale transcriptional drug screens combined
with RNA-seq data of the lung epithelium with SARS-CoV-2 infection as well as the aging lung. To
identify robust druggable protein targets, we propose a principled causal framework that makes use of
multiple data modalities. Our analysis highlights the importance of serine/threonine and tyrosine
kinases as potential targets that intersect the SARS-CoV-2 and aging pathways. By integrating
transcriptomic, proteomic and structural data that is available for many diseases, our drug discovery
platform is broadly applicable. Rigorous in vitro experiments as well as clinical trials are needed to
validate the identified candidate drugs.
Candidates for drug repurposing have mainly been identified based on an understanding of their
pharmacology or based on retrospective analyses of their clinical effects. Recently, also more systematic
computational methods combined with large-scale experimental screens have been employed [1]. The
Connectivity Map (CMap) containing gene expression profiles generated by dosing thousands of small
molecules, including many FDA approved compounds, in a number of human cell lines has been particu-
larly valuable in this regard [2]. Common computational approaches include signature matching, where
the signature of a drug is determined for example using CMap and compared to the reverse signature of
a disease to identify drugs with high correlation [3]. In addition, approaches to identify drug or disease
networks based on known pathways, protein-protein interactions, gene expression or genome-wide asso-
ciation studies have also been employed [4, 5, 6]. To capitalize on the abundance of data, it is critical to
develop computational platforms that can integrate different data modalities including gene expression,
drug targets and signatures, as well as protein-protein interactions. In addition, a drug represents an
intervention in the system and only a causal framework allows predicting the effect of an intervention.
It is therefore critical to capitalize on recent advances in causal inference [7, 8] in particular with respect
to the use of interventional data [9, 10, 11, 12].
Given the current coronavirus disease 2019 (COVID-19) crisis, there is an urgent need for the de-
velopment of robust drug repurposing methods. Coronaviruses belong to the family of positive-strand
RNA-viruses. While most coronaviruses infect the upper respiratory tract and cause mild illness, they
can have serious effects as exemplified by the severe acute respiratory syndrome coronavirus (SARS-CoV)
epidemic and now the SARS-CoV-2 pandemic [13]. Recent studies have shown that coronaviruses use
canonical inflammatory pathways (e.g. NF-κB) of the host cell for their replication, while simultaneously
dampening their outward inflammatory signaling [14, 15]. This delicate partial up and down-regulation
of inflammatory pathways by coronaviruses has represented major challenges for therapeutic interven-
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tions [16]. While the infection rates for these viruses are similar among different age groups, the morbidity
and fatality rates are significantly higher in the aging population [17, 18]. The respiratory system of
aging individuals is characterized by alterations of tissue stiffness [19]. Notably, recent micropatterning
experiments have shown that cells subjected to substrates of different stiffness stimulated with the same
cytokine (TNF-α) exhibit different downstream NF-κB signaling [20]. In a recent commentary, we out-
lined that the cross-talk between coronavirus infection and cellular aging could play a critical role in the
replication of the virus in host cells by differentially intersecting with NF-κB signaling [21]. This suggests
that efforts for drug repurposing should analyze SARS-CoV-2 infected host cell expression programs in
conjunction with aging-dependent programs. While a number of studies are underway that investigate
viral integration/replication and interactions with the host cell [6, 22], to our knowledge the interplay
of SARS-CoV-2 host response and aging has not been explored in the context of drug development and
repurposing.
In this paper, we propose a novel computational platform for drug repurposing, which integrates
transcriptomic, proteomic and structural data with a principled causal framework, and we apply it in
the context of SARS-CoV-2 (Fig. 1). Given the age-dependent pathogenicity of SARS-CoV-2, we first
identify genes that are differentially regulated by SARS-CoV-2 infection and aging based on bulk RNA-
seq data from [23, 24]. We then use an autoencoder, a type of artificial neural network used to learn
data representations in an unsupervised manner [25, 26], to embed the CMap data together with the
SARS-CoV-2 expression data for signature matching to obtain an ordered list of FDA approved drugs. In
particular, we show that overparameterized autoencoders align drug signatures from different cell types
and thus allow constructing synthetic interventions [27, 28] by translating the effect of a drug from one cell
type to another. We then construct a combined SARS-CoV-2 and aging interactome using a Steiner tree
analysis to connect the differentially expressed genes within a protein-protein interaction network [29, 30].
By intersecting the resulting combined SARS-CoV-2 and aging interactome with the targets of the 300
top ranked FDA approved drugs from the previous analysis, we identify serine/threonine and tyrosine
kinases as potential drug targets for therapeutic interventions. Causal structure discovery methods
applied to the combined SARS-CoV-2 and aging interactome show that the identified protein kinase
inhibitors such as axitinib, dasatinib, pazopanib and sunitinib target proteins that are upstream from
genes that are differentially expressed in SARS-CoV-2 infection and aging, thereby validating these drugs
as being of particular interest for the repurposing against COVID-19. While we apply our computational
platform in the context of SARS-CoV-2, our algorithms integrate data modalities that are available for
many diseases, thereby making them broadly applicable.
Results
Differential expression analysis identifies genes that intersect the SARS-CoV-2
host response and aging pathways
Since age is strongly associated with severe outcomes in patients with COVID-19, we sought to analyze
genes differentially expressed in normal versus SARS-CoV-2 infected cells as well as genes differentially
expressed in young versus old individuals. Used as model system for lung epithelial cells and the effect of
SARS-CoV-2 infection, we obtained from [23] RNA-seq samples from normal and SARS-CoV-2 infected
A549 lung alveolar cells as well as A549 cells supplemented with ACE2 (A549-ACE2), a receptor that has
been shown to be critical for SARS-CoV-2 cell entry [31]. Fig. 2a shows the expression of A549-ACE2
cells infected with SARS-CoV-2 in comparison to normal A549-ACE2 cells, with many genes upregulated
as a result of the infection, as expected. Given the availability of A549 data with/without ACE2 and
with/without SARS-CoV-2 infection, we removed genes from this initial list of differentially expressed
genes that were just ACE2-specific or just SARS-CoV-2 infection-specific to extract a more refined
expression pattern of ACE2-mediated SARS-CoV-2 infection (Methods, Fig. 2b). The rationale was to
remove genes linked to the response of the ACE2 receptor to signals other than SARS-CoV-2 infection or
genes involved in the entry of SARS-CoV-2 into the cell through means other than the ACE2 receptor,
which has been shown to be the critical mode of entry in humans [31]. Gene ontology (GO) enrichment
analysis revealed enrichment in mitotic cell cycle as the top term, further supporting removal of these
genes (Supplementary Fig. S1). The remaining 1926 genes are denoted in red in Fig. 2a,b and used
for the subsequent analysis. GO enrichment analysis of these genes revealed that they are significantly
enriched in the type I interferon signaling pathway and defense response to virus in addition to other
GO terms (Fig. 2c). Next, in order to analyze the link between SARS-CoV-2 infection and aging, we
analyzed RNA-seq samples from the lung of different aged individuals collected as part of the Genome
2
Tissue Expression (GTEx) study [24]. Given the stark increase in case fatality rates of COVID-19 after
age 70 [17, 18], we performed a differential expression analysis comparing the youngest group (20-29
years old) and oldest group (70-79 years old), thereby identifying 1923 genes differentially regulated in
aging (Fig. 2d, Supplementary Fig. S2). As shown in Fig. 2e, these genes show a significant overlap
with the 1926 genes found to be differentially regulated by SARS-CoV-2 (p-value= 0.01999, Fisher’s
exact test), thereby confirming results obtained using a different analysis in [32]. Interestingly, these
219 genes that we found to intersect the SARS-CoV-2 infection and aging pathways (Fig. 2e) display
concordant changes in gene expression (i.e. the majority of genes is either upregulated or downregulated
with SARS-CoV-2 infection and aging) as shown by the log2-fold changes in Fig. 2f and Supplementary
Fig. S3a. The association in the directionality of regulation between SARS-CoV-2 infection and aging is
statistically significant (p-value < 2.2 × 10−16, Fisher’s exact test), thereby providing further evidence
for the interplay of SARS-CoV-2 host response and aging as hypothesized in [21]. Fig. 2g shows the
log2-fold changes of the 10 most differentially expressed genes across aging and SARS-CoV-2 infection
(based on the sum of their ranks with Supplementary Fig. S3b showing the distribution of the ranks).
Identification of SARS-CoV-2 infection signature in reduced L1000 gene ex-
pression space
Next, we focused our analysis on identifying the SARS-CoV-2 transcriptional signature, which we then
correlated with the transcriptional signatures of FDA approved drugs in CMap to identify drugs that
could revert the effect of SARS-CoV-2 infection. While this analysis resulting in an initial ranking of
FDA approved drugs did not take the transcriptional signature of aging into account, aging was a critical
component in the final selection of FDA approved drugs described below.
Since gene expression in CMap was quantified using L1000 reduced representation expression profil-
ing [2], which measures gene expression of 1000 representative genes, we first sought to analyze whether
these genes sufficiently capture the transcriptional signature of SARS-CoV-2 infection. For this, we in-
tersected the genes measured both by Blanco et al. [23] and CMap [2], resulting in 911 genes. We found
a statistically significant overlap between the genes identified as differentially expressed by SARS-CoV-2
infection in Fig. 2 and the L1000 genes (p-value=7.94× 10−16, Fisher’s exact test), thereby providing a
rational for using the CMap database for drug identification in this disease context (Fig. 3a). We thus
proceeded to obtain the signature of SARS-CoV-2 infection in the reduced L1000 gene expression space
by projecting the RNA-seq data of A549 cells with and without ACE2-receptor and SARS-CoV-2 infec-
tion onto the shared 911 genes. The resulting signatures of SARS-CoV-2 infection and ACE2-receptor
are visualized using the first two principal components in Fig. 3b. Interestingly, the signature of SARS-
CoV-2 infection (indicated by arrows) was aligned across both A549 and A549-ACE2 cells as well as
across different levels of infection (MOI of 0.2 and 2), suggesting that the SARS-CoV-2 transcriptional
signature was captured robustly by the L1000 genes, thus providing further rational for using CMap to
identify drugs that could reverse the effect of SARS-CoV-2 infection.
Combined autoencoder and synthetic interventions framework to identify
drug signatures and rank FDA approved drugs for SARS-CoV-2
Next, we sought to determine transcriptional drug signatures using the CMap database, which includes
among other cell lines A549. The data was visualized using Uniform Manifold Approximation and
Projection (UMAP) [33] in Supplementary Fig. S4a, showing that the perturbations clustered by cell type
and hence the drug signatures were small relative to the differences between cell types. We intersected
the perturbations from CMap with a list of FDA approved drugs using Slinky [34], resulting in 759
drugs of which 605 were available for A549. After removing batch effects using k-means clustering (see
Methods and Supplementary Fig. S4b), we computed initial signatures of these drugs based on the mean
before and after drug perturbation in A549 cells. Fig. 3c shows a selection of drug signatures in relation
to the signature of SARS-CoV-2 infection visualized using the top two principal components.
Since the effect of a drug can be cell-type specific [35], this standard approach to computing drug
signatures may not allow extrapolating the obtained signatures beyond A549 cells. In order to determine
robust drug signatures and consider also FDA approved drugs that have been dosed on cell lines other
than A549 in CMap, we employed an autoencoder framework. Autoencoders, a particular class of
neural networks where an input is mapped through a latent space to itself, have been widely used for
representation learning [25, 26, 36] and more recently also in genomics and single-cell biology [37, 38, 39].
We trained an autoencoder (architecture described in Supplementary Fig. S5) to minimize reconstruction
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error on CMap data and data from Blanco et al. [23] in the L1000 gene expression space. We then
computed the disease and drug signatures based on the embedding of the data in the latent space.
Interestingly, by comparing the correlations between drug signatures obtained from A549 cells and MCF7
cells (Fig. 3d) as well as HCC515 cells (Supplementary Fig. S7), cell lines with many perturbations in
CMap, it is apparent that the autoencoder aligned the drug signatures across different cell types. While
autoencoders and other generative models have been used for computing signatures of perturbations
also in other works [39, 40], these works have used autoencoders in the standard way to obtain a lower -
dimensional embedding of the data. Motivated by our recent work which, quite counter-intuitively,
described various benefits of using autoencoders to learn a latent representation of the data that is
higher -dimensional than the original space [41], we found that overparameterized autoencoders not only
led to better reconstruction of the data than standardly used autoencoders (Supplementary Fig. S6 and
architectures described in Supplementary Fig. S5), but also to a better alignment of drug signatures
between different cell types (Supplementary Fig. S7). Interestingly, overparameterized autoencoders
provided about the same alignment of drug signatures as using the top three principal components (Fig.
3e), while at the same time allowing a near perfect reconstruction of the original gene expression vectors
from the embedding. Providing additional validation of the latent space embedding obtained by the
overparameterized autoencoder, we found that known ACE2 inhibitors were generally aligned with the
reverse signature of ACE2 in A549 cells (e.g. correlations for moexipril, quinapril and perindopril are all
0.88; see Supplementary Dataset 1). We thus used this latent space embedding to rank the drugs based
on their correlation with the reverse disease signature in A549 cells (Supplementary Dataset 1). Since
overparameterized autoencoders aligned drug signatures across cell types, this embedding also allowed
constructing synthetic interventions [27, 28], i.e., to predict the effect of a drug on A549 cells without
measuring it, by linearly transferring the corresponding drug signature in the latent space from a cell
type where it has been measured. In this way, we obtained an enlarged list of drug signatures, which
we correlated in the latent space with the reverse disease signature to obtain further candidates of FDA
approved drugs for SARS-CoV-2 (Supplementary Dataset 1). To compare the correlations obtained with
the different embeddings, a list of the top ranked drugs is shown in Fig. 3f. Interestingly, it contains
various drugs that were identified also in [6] using a different analysis (clemastine, haloperidol, ribavirin)
or are currently in clinical trials (ribavirin, quinapril).
Steiner tree analysis identifies candidate drug targets by constructing com-
bined SARS-CoV-2 and aging interactome
Our differential expression analysis revealed relevant genes to investigate in the context of SARS-Cov-2
infection and aging, while the combined autoencoder and synthetic interventions analysis provided can-
didate FDA approved drugs for reverting the effect of SARS-CoV-2 infection. Next, we integrated
these two separate analyses to obtain a final list of FDA approved drugs by constructing a combined
SARS-CoV-2 infection and aging protein-protein interactome and intersecting it with the targets of the
candidate drugs (Fig. 4a). For this, we selected the differentially expressed genes identified in Fig. 2f
that showed concordant regulation between aging and SARS-CoV-2 infection and intersected them with
the nodes of the human protein-protein interaction (PPI) network (IRefIndex Version 14 [42]), which
contains 182,002 interactions between 15,759 human proteins along with a confidence measure for each
interaction. This resulted in 162 protein-coding genes, which we call terminals (Supplementary Fig. S8
and Methods). To gain a better understanding of the molecular pathways connecting these terminal
genes, we used a Steiner tree algorithm [30, 43] to determine a “minimal” subnetwork or interactome
within the PPI network that connects these genes (see Methods). A Steiner tree is minimal in that
it is a minimum weight subnetwork that connects the terminals. As edge weights in the PPI network
we used 1 minus the confidence in the corresponding interactions so as to favor high-confidence edges.
After a careful sensitivity analysis to select the various tuning parameters (Methods and Supplementary
Fig. S9), this resulted in an interactome containing 252 nodes and 1,003 edges (Fig. 4b and Supplemen-
tary Fig. S10). Interestingly, the interactome contained five genes whose corresponding proteins have
been found in [6] to interact with SARS-Cov-2 proteins (EXOSC5, FOXRED2, LOX, RBX1, RIPK1).
The 2-nearest-neighborhoods of these proteins are shown in Fig. 4c. Another Steiner tree analysis re-
vealed that two additional SARS-Cov-2 interaction partners (CUL2 and HDAC2) were connected to the
identified interactome via few high-confidence edges (Supplementary Fig. S11 - S13).
Next, we intersected the interactome with the targets of the candidate drugs identified in the previous
analysis. A compound was considered if its signature matched the reverse SARS-CoV-2 signature with
at least a correlation of 0.86, resulting in about 300 FDA approved drugs (see Methods). The targets of
4
these drugs were determined using DrugCentral [44, 45] and filtered for high affinity (activity constants
lower than 10µM , a common threshold used in the field for Ki, Kd, IC50 or EC50). Interestingly, the
resulting drugs, shown in Fig. 4d, consisted (with few exceptions) of protein kinase inhibitors (e.g. axi-
tinib, dasatinib, pazopanib, sunitinib). To analyze the specificity of our findings to SARS-Cov-2 infection
in aged individuals, we repeated the above analysis without using the GTEx data. This resulted in an
interactome containing 1,052 edges across 270 nodes, 42 of which (15%) were also present in the inter-
actome taking age into consideration (Supplementary Fig. S14). This pure SARS-CoV-2 interactome
contained 6 SARS-Cov-2 interaction partners (ETFA, GNB1, NUP62, RBX1, RIPK1, SNIP1). Drugs
targeting proteins in this interactome belonged to several families including serotonin inhibitors (cloza-
pine, cyproheptadine, desipramine, methysergide), histamine H1 blockers (clemastine, cyproheptadine,
ketotifen), tyrosine kinase inhibitors (including axitinib, dasatinib, pazopanib, sunitinib) and HDAC in-
hibitors (vorinostat, belinostat). This analysis shows that taking aging into account acted as a valuable
filter for the identification of drugs.
Causal structure discovery methods validate serine/threonine and tyrosine
kinases as critical targets in SARS-CoV-2 infection in the elderly.
Finally, in order to suggest putative causal drug mechanisms and validate the predicted drugs for COVID-
19, we supplemented the PPI analysis with causal structure discovery. Since the edges in the PPI network
and hence in the SARS-CoV-2 and aging interactome are undirected, it is a-priori not clear whether a drug
that targets a node in the interactome has any effect on the differentially expressed terminal nodes, since
the target may be downstream of these nodes (Fig. 5a). To understand which genes can be modulated
by a drug, it is therefore critical to obtain a causal (directed) network. We obtained single-cell RNA-seq
data for A549 cells from [46] and intersected it with the genes present in the combined SARS-CoV-2 and
aging interactome. To learn the (causal) regulatory network among these genes, we took advantage of
recently developed causal structure discovery algorithms, in particular the greedy sparsest permutation
(GSP) algorithm: it performs a greedy search over orderings of the genes to find the sparsest causal
network that best fits the data ,and it has been successfully applied to single-cell gene expression data
before [11, 12, 47]. To validate the obtained causal model and benchmark the performance of GSP to
other prominent causal structure discovery algorithms including PC and GES [48], we took advantage of
the gene knockout and overexpression data available from CMap. A causal model should allow predicting
the effect of such interventions. Thus, for each such gene knockout and overexpression experiment in
CMap that targeted a gene in the interactome, we inferred the genes whose expression changed as a
result of the intervention, when compared to control samples (Methods and Supplementary Fig. S15a).
We then constructed receiver operating characteristic (ROC) curves to evaluate GSP, PC and GES by
varying their tuning parameters and counting an edge i → j as a true positive if intervening on gene i
resulted in a change in the expression of gene j and a false positive otherwise, thereby showing that GSP
exceeded random guessing based on the PPI network (p-value=0.0177, see Methods) and outperformed
the other methods (Supplementary Fig. S15b).
Having established that the causal network obtained by GSP can be used to predict the effect of an
intervention, we turned to analyzing the regulatory effects of the identified candidate drugs on the SARS-
CoV-2 and aging interactome in A549 cells. The main connected component of the corresponding causal
graph is shown in Fig. 5a (see also Supplementary Fig. S16a) highlighting the drug targets and the genes
that were found to be differentially expressed by SARS-CoV-2 infection and aging. We then traced the
possible downstream effects for each identified drug, thereby finding that the protein kinase inhibitors and
HDAC inhibitors could target the majority of differentially expressed genes in this connected component
(Table S1). Similarly, we traced the downstream effects for each gene in the interactome that can
be targeted by one of the identified drugs, thereby finding that EGFR, FGFR3, HDAC1, HSP90AA1,
IRAK1, PAK1, RIPK1, RIPK2, STK3 all have downstream nodes in the interactome with RIPK1 having
the largest number of them (127). To validate these results in a broader context, we obtained single-cell
RNA-seq data from [49] and repeated the analysis in AT2 cells, which have been shown to be critically
affected by SARS-CoV-2 in humans [31]. The resulting causal network for AT2 cells (Supplementary
Fig. S16b) is similar to the one for A549 cells, intersecting it in 55.3% of the edges, with EGFR, HDAC1,
HSP90AA1, IRAK1, RIPK1 and RIPK2 all having descendants in the interactome, and targets of protein
kinase inhibitors and HDAC inhibitors being particularly central (Table S1). To analyze the most critical
targets for the crosstalk between SARS-CoV-2 and aging, we repeated the analysis in the interactome
obtained without taking aging into account (Supplementary Fig. S16c). Interestingly, while HDAC1 and
HSP90AA1 continued to have widespread effect, the number of genes downstream of RIPK1 changed
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drastically to just 1, suggesting that RIPK1 plays a critical role in the SARS-CoV-2 and aging cross-talk.
In line with this, while the effect of HDAC inhibitors remained similar in the analysis without ageing,
the effect of protein kinase inhibitors changed drastically (Table S1). Collectively, our combined analysis
points to protein kinase inhibitors, and it in particular highlights RIPK1, a serine/threonine-protein
kinase, as one of the main targets against SARS-CoV-2 infections with a highly age-dependent role
and the largest number of downstream differentially expressed genes in the combined SARS-CoV-2 and
ageing interactome.
Discussion
The repurposing of drugs for SARS-CoV-2 has been a major challenge given the many pathways involved
in host-pathogen interactions and the intricate interplay of SARS-CoV-2 with inflammatory pathways [14,
13, 15, 16]. Interestingly, while both young and old individuals are susceptible to SARS-CoV-2 infection,
the virus’ pathogenicity is significantly more pronounced in the elderly [17, 18]. Since the mechanical
properties of the lung tissue change with aging [19], this led us to hypothesize an interplay between viral
infection/replication and tissue aging [21], suggesting that this could play an important role in drug
discovery programs. While ongoing drug repurposing efforts have analyzed host-pathogen interactions
and the associated gene expression programs [6, 23], they have lacked an integration with aging. More
generally, while a number of data-driven and experimental approaches have been proposed for drug
identification and repurposing [1], a platform that systematically integrates different data modalities
including transcriptomic, proteomic and structural data into a principled causal framework to predict
the effect of different drugs has been missing.
By combining bulk RNA-seq data from GTEx [24] and Blanco et al. [23], we identified a critical group
of genes that were differentially expressed by aging and by SARS-CoV-2 infection. While previous anal-
ysis relied primarily on contrasting the expression in cells with and without SARS-CoV-2 infection [32],
we made an attempt to separate the effect of the ACE2 receptor alone and the effect of SARS-CoV-2 in
cells without ACE2 receptor to extract a more refined differential expression pattern of ACE2-mediated
SARS-CoV-2 infection. While previous computational efforts to repurpose drugs have mainly considered
two approaches: (1) identifying drug targets by analyzing disease networks based for example on PPI or
transcriptomic data [5, 4, 6], and (2) identifying drugs by matching their signature (for example obtained
from the CMap project [2]) to the reverse disease signature [3], we developed a principled causal frame-
work that encompasses these two approaches. First, in order to ensure that the CMap database, which
measures expression using 1000 representative genes, would be useful in the context of SARS-CoV-2, we
validated that the intersection of these genes with the SARS-CoV-2 differentially expressed genes was
significant. Second, to establish drug signatures based on the CMap database, we employed a particular
autoencoder framework [41]. Rather unintuitively, we showed that using an overparameterized autoen-
coder, i.e. by using an autoencoder not to perform dimension reduction as usual but to instead embed
the data into a higher-dimensional space, aligned the drug signatures across different cell types. This
allowed constructing synthetic interventions, i.e., to predict the effect of a drug on a cell type without
measuring it by using other cell types to infer it. Third, to identify drug targets in the pathways in-
tersecting SARS-CoV-2 and aging, we connected the differentially expressed genes in the PPI network
using a Steiner tree analysis [30] and intersected the resulting interactome with high-affinity targets of
the drugs obtained using the overparameterized autoencoder framework. Finally, while computational
drug discovery programs have been largely correlative [1], we made use of recent causal structure discov-
ery algorithms [11, 47, 48] to validate the identified drug targets and their downstream effects, thereby
identifying protein kinase inhibitors such as axitinib, dasatinib, pazopanib, and sunitinib as drugs of
particular interest for the repurposing against COVID-19.
Among the various protein kinases, in particular from the family of serine/threonine-protein kinases,
identified by our drug repurposing pipeline, RIPK1 was singled out by our causal analysis as being
upstream of the largest number of genes that were differentially expressed by SARS-CoV-2 infection
and aging, while losing its central role in the corresponding gene regulatory network without taking
aging into account. Notably, RIPK1 has been shown to bind to SARS-CoV-2 proteins [6] and has also
been found to be in an age-dependent module [32]. RIPK1 belongs to an interesting family of proteins
comprising of a kinase domain on the N terminus and a death domain on the C terminus; activation of the
kinase domain has been associated with epithelial cell homeostasis, while activation of the death domain
leads to triggering necroptotic or apoptotic pathways [50, 51], the death pathways potentially triggering
tissue fibrosis [52]. Interestingly, our differential expression analysis found RIPK1 to be upregulated with
SARS-COV-2 infection. We hypothesize that upon SARS-CoV-2 infection in older individuals the death
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pathways may be favored, thereby leading to fibrosis and increased blood clotting. Consistent with this,
recent post-mortem lung tissue biopsies of SARS-CoV-2 human patients revealed a fibrotic epithelium
and increased blood clotting [53, 54].
Collectively, these results highlight the importance of RIPK1 in the interplay between SARS-CoV-2
infection and aging as a potential target for drug repurposing programs. There are various drugs cur-
rently approved that non-specifically target RIPK1 (such as pazopanib and sunitinib) as well as under
investigation that are highly specific to RIPK1 [55, 56]. Given the distinct pathways elicited by RIPK1,
there is a need to develop appropriate cell culture models that can differentiate between young and aging
tissues to validate our findings experimentally and allow for highly specific and targeted drug discovery
programs. While our work identified particular drugs and drug targets in the context of COVID-19,
our computational platform is applicable well beyond SARS-CoV-2, and we believe that the integration
of transcriptional, proteomic and structural data with network models into a causal framework is an
important addition to current drug discovery pipelines.
Methods
Bulk gene expression data
The RNA-seq gene expression data related to SARS-CoV-2 infection in A549 and A549-ACE2 cells was
obtained from [23] under accession code GSE147507. The RNA-seq data of lung tissues for the aging
analysis was downloaded from the GTEx Portal (https://gtexportal.org/home/index.html) along with
metadata containing the age of the individual from whom the RNA-seq sample was obtained. The
RNA-seq raw read counts were transformed into quantile normalized, log2(x+ 1) scaled RPKM values,
following the normalization performed in [2].
Differential expression analysis
For differential expression analysis, we focused on genes that were highly expressed, filtering out any
genes with log2(RPKM +1) < 1 for all considered datasets. In order to determine the ACE2-mediated
SARS-CoV-2 genes, we computed three different log2-fold changes based on the data from [23]. Namely,
we defined as ACE2-mediated SARS-CoV-2 genes all genes that had an absolute log2-fold change between
A549-ACE2 cells infected with SARS-CoV-2 and A549-ACE2 cells above threshold, excluding genes that
had an absolute log2-fold change above the same threshold in A549-ACE2 cells versus A549 cells and also
excluding genes that had an absolute log2-fold change above the same threshold in A549 cells infected
with SARS-CoV-2 versus normal A549 cells. In other words, the ACE2-mediated SARS-CoV-2 genes
were defined as the genes denoted in red in the Venn diagram in Fig. 2b (with pink, brown and yellow
subsets removed). The absolute log2-fold change threshold was determined such that the number of
ACE2-mediated SARS-CoV-2 genes was 10% of the protein coding genes.
In order to determine the age associated genes, we analyzed lung tissue samples obtained from the
GTEx portal (https://gtexportal.org/home/index.html) from individuals of varying ages. We computed
the absolute log2-fold change between samples of the lung tissue from older (70-79 years old) and younger
(20-29 years old) individuals, defining the age associated genes as the top 10% of protein coding genes
with highest absolute log2-fold change. We also considered defining age-associated genes based on the
absolute log2-fold change comparing individuals who are 20-29 years old versus 60-79 years old, which
yielded similar age-associated genes, with 1339 out of the 1923 genes in common between the two sets
as shown in Supplementary Fig. S2b.
Gene ontology enrichment analysis
Gene ontology analysis was performed on a given gene set using GSEApy, keeping the top 10 gene
ontology biological process terms with lowest p-values. All reported terms had p-values ≤ 0.05, after
adjusting for multiple hypothesis testing using the Benjamini–Hochberg procedure.
L1000 gene expression data from CMap
The CMap data measured via L1000 high-throughput reduced representation expression profiling, which
quantifies the expression of 1000 landmark genes, was obtained from [2] under accession code GSE92742.
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We chose level 2 data, truncated to only the genes that were also measured by [23], and then performed
log2(x+ 1) scaling and min-max scaling on each of the resulting 911-dimensional expression vectors.
Combined autoencoder and synthetic interventions framework
We first describe our training procedures for the autoencoder framework. CMap contains a total of
1,269,922 gene expression vectors and we performed a 90-10 training-test split resulting in 1,142,929
training examples and 126,993 test examples. We selected the best model by applying early stopping
with an upper bound on the number of total epochs being 150. Note that this is well past the usual
early stopping method of applying a patience strategy with a patience of at most 10 epochs [57]. All
hyperparameter settings, optimizer details, and architecture details are presented in Supplementary
Fig. S5c. To summarize, we considered a range of fully connected autoencoders with varying depth,
width, and nonlinearity, and we used Adam with a learning rate of 10−4 for optimization. To compute
the drug signatures via the trained autoencoder, we used as embeddings the output of the first hidden
layer prior to application of the activation function.
Drug signatures for the A549 cells (and similarly for the MCF7 and HCC515 cells) in CMap were
computed by taking the difference between the mean embedding for the A549 samples with drug and the
mean embedding for the A549 control (DMSO) samples. To remove batch effects, we performed k-means
clustering of the control samples in the embedding space and removed all points falling in the smaller of
the two clusters (see Supplementary Fig. S4b).
Next, we briefly describe the synthetic interventions framework and how the embedding from our
trained overparameterized autoencoder is used for this. The traditional application of synthetic inter-
ventions [27, 28] in the context of drug repurposing would proceed as follows: when a drug signature is
unavailable on a given cell type but is available on other cell types, we would express the cell type as a
linear combination of the other cell types and use this linear combination to predict the signature on the
cell type for which data is unavailable. Since we demonstrated that over-parameterized autoencoders
align drug signatures between different cell types (Supplementary Fig. S7), instead of using a linear com-
bination of drug signatures across cell types, we can simply use one of the available drug signatures as the
synthetic intervention. In particular, in this work, we used drug signatures on MCF7 cells to construct
synthetic interventions for A549 cells. We also considered drug signatures on HCC515 cells; however,
there was only one FDA approved drug that was applied to HCC515 cells which was not also applied
to A549 cells in CMap. While this analysis did not help to increase the number of considered drugs, we
used the data on HCC515 cells in conjunction with the data on A549 and MCF7 cells to validate that
the overparameterized autoencoder aligns the signatures of drugs between different cell types (Fig. 3d
and Supplementary Fig. S7).
Cosine similarity between perturbations
For each cell type and perturbation, we computed a cell-type specific “perturbation signature”, which is
defined as the difference between the average gene expression of a cell type under that perturbation and
under the control perturbation, DMSO. Then, for each perturbation, we computed the cosine similarity
a·b
|a||b| between the perturbation vectors for all pairs of cell types which received that perturbation in
CMap. For example, daunorubicin was applied to 14 cell types in cMap, resulting in
(
14
2
)
= 91 cosine
similarities associated with daunorubicin. All cosine similarities were plotted (Fig. 3e).
Steiner tree analysis
Human protein-protein interaction (PPI) network
A weighted version of the publicly available IRefIndex v14 human PPI network [42] was retrieved from
the OmicsIntegrator2 GitHub repository (http://github.com/fraenkel-lab/OmicsIntegrator2). The in-
teractome contains 182,002 interactions between 15,759 proteins. Each interaction e has an associated
cost c(e) = 1−m(e) where the score m(e) is obtained using the MIScore algorithm [58], which quantifies
confidence in the interaction e based on several evidence criteria (e.g. number of publications reporting
the interaction and corresponding detection methods).
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Human-SARS-Cov-2 PPI network
A high-confidence host-pathogen interaction map of 27 SARS-Cov-2 viral proteins with HEK293T
proteins [6] was retrieved from NDEx (http://www.ndexbio.org/#/network/5d97a04a-6fab-11ea-bfdc-
0ac135e8bacf), which reports interactions with 332 human proteins.
Drug-target interaction data
Data on the targets of drugs was obtained from DrugCentral (http://drugcentral.org/download), an on-
line drug information resource, which includes drug-target interaction data extracted from the literature
along with metrics (such as inhibition constant Ki, dissociation constant Kd, effective concentration
EC50, and inhibitory concentration IC50) measuring the affinity of the drug for its target [44, 45].
Drugs in the database are approved by the FDA and may also be approved by other regulatory agencies
(such as the EMA). From this database, we filtered out compounds targeting non-human proteins. We
also discarded drug-target pairs with affinity metrics (Ki, Kd, EC50 or IC50) higher than 10µM , a com-
monly used threshold in the field. Based on this filtering we obtained a data set containing 12,949 high
affinity drug-target pairs involving 1,457 unique human protein targets and 2,095 unique compounds.
This dataset was further restricted to drugs predicted to reverse the SARS-Cov-2 signature (correlation
greater than 0.86 in the overparameterized autoencoder embedding). As a result, the final drug-target
data set included information on 2,296 drug-target pairs involving 652 unique human gene targets and
117 unique FDA approved drugs.
Prize-collecting Steiner forest algorithm
The Prize-Collecting Steiner Forest (PCSF) problem is an extension of the classical Steiner tree problem:
Given a connected undirected network with non-negative edge weights (costs) and a subset of nodes, the
terminals, find a subnetwork of minimum weight that contains all terminals. The resulting subnetwork
is always a tree, which in general contains more nodes than the terminals; these are known as Steiner
nodes. In the special case when there are only 2 terminals, this boils down to finding the shortest path
between these nodes. The Steiner tree problem in general is known to be NP-complete, but various
approximations are available. The PCSF problem generalizes this problem by introducing prices for
the terminals (in addition to the edge costs already present in the Steiner tree problem) and a dummy
node connected to all terminals. The problem is then to find a connected subnetwork that minimizes an
objective function involving the cost of selected edges and the prizes of terminals that are missing from
the subnetwork as detailed below; we used OmicsIntegrator2 to solve this optimization problem [30].
To formally introduce the objective function, let G = (V,E, c(·), p(·)) denote the undirected PPI
network with protein set V (containing N proteins), interaction set E, edge cost function c(·), set of
terminals S ⊂ V (containing N proteins) and attributed prizes p(·). The version of the PCSF problem
solved by OmicsIntegrator2 [30] and used in this article consists of finding a connected subnetwork
T = (VT , ET ) of the modified graph G
∗ = (V ∪ {r}, E ∪ {{r, s} : s ∈ S}) that minimizes the objective
function
ψ(T ) = b
∑
v/∈VT
p(v) +
∑
e∈ET
c∗(e)
The node r is a dummy root node connecting all terminals in the network. The parameter b ∈ R+
linearly scales the node prizes (which are non-zero for terminal nodes exclusively), and the modified edge
cost function c∗(·) can be expressed as follows. For any edge e = {x, y}
c∗(e) =
{
c(e) +
dxdy
dxdy+(N−dx−1)(N−dy−1)10
g if e ∈ E
w if e ∈ {{r, s} : s ∈ S} (1)
where dx denotes the degree of node x in G and g, w ∈ R+ are tuning parameters. If the resulting tree
contains the root node r, r is removed from the tree, and the output is an ensemble of trees, a forest.
The final output, the interactome, is the subnetwork in the PPI network induced by the nodes of this
forest.
Selection of terminal nodes
Results from the differential expression analysis yielded 219 protein-coding genes that were associated
with both aging and SARS-Cov-2 infection. Of particular interest among these genes were 181 genes
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that showed concordant regulation, i.e. they were either upregulated in both SARS-Cov-2 infection and
aging or downregulated in both SARS-Cov-2 infection and aging. Intersecting the proteins corresponding
to these 181 genes with proteins in the IREF interactome resulted in 162 proteins. These 162 proteins
were selected as terminal nodes for the PCSF algorithm and prized according to their absolute log2-fold
change between SARS-Cov-2-infected A549-ACE2 cells and normal A549-ACE2 cells (Supplementary
Fig. S8)
Parameter sensitivity analysis
Running the PCSF algorithm in the OmicsIntegrator2 required specifying three tuning parameters: g,
w and b. In order to guarantee the robustness of the resulting network with respect to moderate changes
in these parameters, we selected the parameters based on a sensitivity analysis.
The parameter g modifies the background PPI network by imposing an additive penalty on each
edge based on the degrees of the corresponding vertices. It reduces the propensity of the algorithm to
select hub nodes connecting many proteins in the interactome. While this feature may be relevant in
certain biological applications, it was not necessarily the case in our work since high degree nodes may
be of interest for the purpose of drug target identification. In the cost function in Equation (1), the
absence of penalty corresponds to g = −∞. However the OmicsIntegrator2 implementation only allows
for g ∈ R+. In Supplementary Fig. S9a1, we reported boxplots of penalized edge costs in the IREF
interactome for different values of g. These boxplots suggest that the hub penalty parameter g = 0
yields similar edge costs to the desired setting where g = −∞. For this reason we chose the value g = 0
in all OmicsIntegrator2 runs in this work.
The parameter w corresponds to the cost of edges connecting terminal nodes to the dummy root r.
This parameter influences the number of trees in the Steiner forest. If w is chosen too low compared to
the typical shortest path cost between two terminals, a trivial solution will connect all terminal nodes
via r, leading to fully isolated terminals in the final forest. For high values of w the PCSF algorithm
will not include the root r and output a connected network. Based on the histogram of the cost of the
shortest path between any two terminals in the IREF interactome reported in Supplementary Fig. S9a2,
we ran a sensitivity analysis for w in the range [0.2, 2].
The parameter b linearly inflates the prizes of terminal nodes in the objective function. Higher values
of b result in more terminal nodes in the final PCSF. We analyzed edge costs in the network to determine
a suitable range for b so as to include many terminal nodes in the resulting interactome. Supplementary
Fig. S9a1 shows that the maximum edge cost in the network for g = 0 was lower than 1, which meant
that making b of order greater than 1 was necessary to ensure that trading off cost of edges added and
prizes collected in the solution would rarely require discarding a terminal node. For this reason we ran
a sensitivity analysis for b in the range [5, 50].
Based on the previous considerations we fixed g = 0 and ran a sensitivity analysis as described in
Supplementary Fig. S9b with w ∈ {0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2} and b ∈ {5, 10, 15, 20, 25, 30,
35, 40, 45, 50}. We obtained 100 PCSFs, each corresponding to a particular choice of (w, b). All of them
included the entire terminal set S, a desired property resulting from the chosen range of the values of
b. To analyze the robustness of the resulting networks to changes in the parameters, we analyzed the
matrix M ∈ [0, 1]100×100 defined by
Mij =
∣∣{ nodes innetwork i} ∩ { nodes innetwork j} ∩ C∣∣∣∣({ nodes innetwork i} ∪ { nodes innetwork j}) ∩ C∣∣
for every pair of PCSFs i and j corresponding to parameters (wi, bi) and (wj , bj), respectively. Supple-
mentary Fig. S9c displays heatmaps of this matrix. We considered three different node sets C, namely
the set of all nodes in the input PPI network (Supplementary Fig. S9c1), the subset of terminal nodes
(C = S, Supplementary Fig. S9c2) and the subset of SARS-Cov-2 interaction partners (Supplementary
Fig. S9c3). Supplementary Fig. S9c1, S9c2, S9c3 illustrate that choosing any (w, b) ∈ [1.2, 2] × [5, 50]
led to the same connected PCSF with 252 nodes and 1,003 edges. This network is robust to moderate
parameter changes for w and b. Collectively, this sensitivity analysis motivated the choice of g = 0,
w = 1.4 and b = 40 used to obtain the interactome in Fig. 4b, where nodes are grouped by general
function. The same interactome is presented in Supplementary Fig. S10 with nodes grouped by general
process. Note that since this interactome included all terminals and did not include the root node, it is
equivalent to the solution of the classical Steiner tree problem.
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Neighborhood analysis
For the interactomes obtained in this work, we reported 2-nearest-neighborhoods of genes of interest in
Fig. 4c for the interactome of Fig. 4b, in Supplementary Fig. S13 for the interactome of Supplementary
Fig. S12, and in Supplementary Fig. S14d for the interactome in Supplementary Fig. S14c. Depending on
the interactome, genes of interest include SARS-Cov-2 interaction partners (e.g. EXOSC5, FOXRED2,
LOX, RBX1, RIPK1) as well as genes of potential therapeutic interest (e.g. HDAC1, EGFR). Neighbor-
hood plots were enriched with information such as SARS-Cov-2 interaction partners and FDA approved,
high affinity (based on data from DrugCentral) drugs with high correlation to the reverse SARS-Cov-2 in-
fection signature. To improve legibility of the neighborhood networks, we discarded the highly connected
hub node UBC (connected to 62% of proteins in the IREF network). To further improve legibility, we
applied an upper threshold on edge cost (i.e., only visualizing high confidence edges) when the neighbor-
hood networks were too densely connected. We generally chose this threshold at 0.53, with the exception
of the LOX neighborhood (0.58) and the FOXRED2, ETFA and GNB1 neighborhoods (no thresholding).
For each edge e in a given neighborhood, we defined the min-max scaled edge confidence C(e) as
C(e) =
maxe′∈E c(e′)− c(e)
maxe′∈E c(e′)−mine′∈E c(e′) ∈ [0, 1]
where E denotes the edge set of the corresponding interactome and c(e) denotes the cost of edge e in the
PPI network. This confidence metric was used to color edges in the neighborhood plots.
Addition of SARS-Cov-2 interaction partners to the terminal node list
In order to understand which other SARS-CoV-2 protein interaction partners were in the neighborhood
of the identified interactome, we also ran the PCSF algorithm on the IREF PPI network using the
SARS-Cov-2 and aging terminal list augmented with all known SARS-Cov-2 interaction partners. All
SARS-Cov-2 interaction partners (with the exception of EXOSC5, FOXRED2 and LOX which were
already present in the original terminal gene list) were given a small prize p. This prize was chosen
by sensitivity analysis over a range of possible values from p = 0 (5 SARS-Cov-2 interaction partners
initially selected by the method: EXOSC5, FOXRED2, LOX, RBXL1, RIPK1) to p = 0.02, beyond
which all 332 known SARS-Cov-2 interaction partners belonged to the computed interactome. Fine-
grained analysis revealed that choosing p ∈ [4× 10−4, 10−3] leads to interactomes which include a stable
set of 7 SARS-Cov-2 interaction partners, the 5 present initially plus CUL2 and HDAC2 (Supplementary
Fig. S11a). Supplementary Fig. S11b-S11c display heatmaps of the matrix M ∈ [0, 1]16×16 defined as
Mij =
∣∣({ nodes innetwork i} \ { nodes innetwork j}) ∩ C∣∣
|{ nodes innetwork i} ∩ C|
for every pair of PCSFs i and j corresponding to parameters pi and pj , respectively. For the sensitivity
analysis, we considered two different node sets C, namely the set of all nodes in the input PPI network
(Supplementary Fig. S11b) as well as the subset of SARS-Cov-2 interaction partners (Supplementary
Fig. S11c). Supplementary Fig. S11b shows that the obtained interactome was stable over the range
p ∈ [7× 10−4, 10−3]. Supplementary Fig. S11c shows that all SARS-Cov-2 interaction partners collected
in the interactome when p ∈ [7 × 10−4, 10−3] were also collected for higher values of p, which is a
consequence of the observation from Supplementary Fig. S11b. We used the value p = 8 × 10−4 for all
subsequent analyses and figures, including Supplementary Fig. S12 and Supplementary Fig. S13.
Single-cell RNA-seq analysis
Single-cell RNA-seq for A549 cells was obtained from GSE81861 [46], where each entry in the ma-
trix represents the gene expression (FPKM) of gene i in cell j. We preprocessed the data, keep-
ing only genes that had a nonzero gene expression value in more than 10% of the cells, followed by
log2(x + 1) transformation of the data. Single-cell RNA-seq data for AT2 cells was obtained from
http://www.nupulmonary.org/resources associated with [49]. In order to avoid batch effects, we subset
the data to include cells only from Donor 7 since that donor had the largest number of AT2 cells collected
(4002 cells). We preprocessed the data using the same threshold as for A549 cells for filtering out genes
across cells. Since single-cell RNA-seq data for AT2 cells was not yet normalized, we normalized the
expression values across genes for each cell by the total RNA count for that cell, followed by log2(x+ 1)
transformation of the data as for A549 cells.
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Evaluation of causal structure discovery algorithms
Prior to reporting the results of learning gene regulatory networks on A549 and AT2 cells, we bench-
marked several causal structure discovery methods on the task of predicting the effects of interventions
using gene knockout and overexpression data collected on A549 cells as part of the CMap project [2],
similar to prior evaluations of causal methods [11, 12]. We estimated the gene regulatory network un-
derlying the identified interactome in A549 cells using the prominent causal structure discovery methods
PC, GES and GSP [8, 48, 47]. Since not all edge directions are identifiable from purely observational
data, these methods output a causal graph containing both directed and undirected edges. Since the
advantage of causal networks is their ability to predict the effects of interventions on downstream genes,
we evaluated these methods using interventions collected in CMap. In the following, we first describe
how we estimated the effects of interventions based on the CMap data to use as ground truth for eval-
uating causal structure discovery methods. We focused our evaluation on genes and interventions that
are shared between the combined SARS-CoV-2 and aging interactome and CMap knockout and overex-
pression experiments, resulting in 32 genes and 41 interventions (note that the number of interventions
is larger than the number of genes, since in CMap interventions have been performed on genes that
are not part of the L1000 landmark genes, but are contained in the interactome). We formed a ma-
trix of genes by interventions, where each (i, j)-entry in the matrix represents the log2-fold change in
expression of gene i when gene j was intervened on in comparison to the expression of gene i without
intervention. We denoted by Q the binary matrix of intervention effects with Qij = 1 if the sign of the
log2-fold change for the (i, j) entry was opposite for knockout and overexpression interventions to filter
out unsuccessful interventions, the rational being that knockout and overexpression should have opposite
downstream effects. Thus Qij = 1 denotes that perturbing gene j effects gene i and hence that gene i is
downstream of gene j (Supplementary Fig. S15a). Taking this matrix of interventional effects, Q, as the
ground truth, we estimated the causal graph using the PC, GES and GSP algorithms and determined
the corresponding ROC curve, counting and edge from j → i as a true positive if Qij = 1 and a false
positive otherwise (Supplementary Fig. S15b). In order to statistically evaluate whether the different
algorithms performed better than random guessing, we sampled causal graphs (from an Erdo¨s-Renyi
model, where the edges were directed based on a uniformly sampled permutation) with different edge
probabilities from the PPI network and calculated the corresponding number of true and false positives.
For each false positive level, we created a distribution over true positives based on the sampled random
causal graphs and calculated the p-value for the number of true positives obtained from the PC, GES
and GSP algorithms. We combined the p-values across different numbers of false positives using Fisher’s
method and used this combined p-value for evaluating whether the PC, GES and GSP algorithms were
significantly different from random guessing.
Causal structure discovery for learning gene regulatory networks
In order to learn the gene regulatory networks governing A549 and AT2 cells, we used the recent structure
discovery method GSP [47, 11, 12] on single-cell RNA-seq data from A549 cells as well as AT2 cells
with the PPI network on 252 nodes as a prior. We used GSP since based on the previous analysis it
outperformed the PC and GES algorithms in terms of ROC analysis on predicting the effect of gene
knockout and overexpression experiments in A549 cells (p-value = 0.0177 for GSP, p-value = 0.0694 for
GSP and p-value = 0.5867 for GES); in addition, GSP is also preferable from a theoretical standpoint,
since it is consistent under strictly weaker assumptions than the PC and GES algorithms [47]. To
obtain an estimate of the causal graph that is robust across hyperparameters and data subsampling, we
used stability selection [59]. In short, stability selection estimates the probability of selection of each
edge by running GSP on subsamples of the data. Aggregating selection probabilities across algorithm
hyperparameters (in this case the α-level for conditional independence testing), edges with high selection
probability (0.3 for A549 cells and 0.4 for AT2 cells) were retained. The threshold for AT2 cells was
chosen so as to approximately match the number of edges in the A549 network.
Data and code availability
All data used in this work is publicly available from the sources mentioned. We relied on open source
code for the analysis (including OmicsIntegrator2, the R package pcalg, as well as the python packages
causaldag, GSEApy, networkx, numpy, pandas, PyTorch, scikit-learn, scipy). A comprehensive GitHub
repository containing all data and code will be made available upon publication of the manuscript.
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Figure 1: Overview of computational drug repurposing platform for COVID-19. (a) COVID-19 is associ-
ated with more severe outcomes in older individuals, suggesting that gene expression programs associated
with SARS-CoV-2 and aging must be analyzed in tandem. A potential hypothesis regarding the cross-
talk between SARS-CoV-2 and aging relies on changes in tissue stiffness in older individuals, outlined
in [21]. (b) In order to identify potential drug candidates for COVID-19, we integrated RNA-seq data
from SARS-CoV-2 infected cells (obtained from [23]) and RNA-seq data from the lung tissue of young
and old individuals (collected as part of the GTEx project [24]) with protein-protein interaction data
(from [42]), drug-target data (from DrugCentral [45]) and the large-scale transcriptional drug screen
CMap [2]. (c) Based on this data, we develop a novel drug repurposing pipeline, which consists of first,
mining relevant drugs by matching their signatures with the disease signature in the latent embedding
obtained by an overparameterized autoencoder and sharing data across cell types to obtain missing drug
signatures via synthetic interventions. Second, we identify a disease interactome within the protein-
protein interaction network by identifying a minimal subnetwork that connects the genes differentially
expressed by SARS-CoV-2 infection and aging using a Steiner tree analysis. Third, we validate the
drugs identified in the first step that have targets in the interactome by identifying the potential drug
mechanism using causal structure discovery.
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Figure 2: Identification of differentially regulated genes in SARS-CoV-2 infection and aging. (a) Gene
expression (log2 RPKM + 1) of A549-ACE2 cells infected with SARS-CoV-2 versus normal A549-ACE2
cells. Genes associated with ACE2-mediated SARS-CoV-2 infection after removing just ACE2-specific
or just SARS-CoV-2 infection-specific genes are shown in red. (b) Venn diagram, showing the number of
genes in sets considered for obtaining the 1926 genes in the red subset and shown in red in (a) associated
with ACE-2 mediated SARS-Cov-2 infection. (c) Top 10 gene ontology terms associated with SARS-
CoV-2 infection (adjusted p-value < 0.05). (d) Gene expression (log2 RPKM + 1) of cells collected
from lung tissue of older (70-79 years old) versus younger (20-29 years old) individuals. Differentially
expressed genes associated with aging are shown in blue and genes that are associated with both aging and
SARS-CoV-2 are shown in orange. (e) Venn diagram of genes associated with SARS-CoV-2 and aging;
intersection is significant (p-value = 0.01999, Fisher’s exact test). (f) Heatmap of log2-fold changes of
differentially expressed genes shared by SARS-CoV-2 and aging; most genes show concordant expression,
i.e., they are both upregulated or both downregulated with SARS-CoV-2 infection and ageing. (g) Table
of the top 10 most differentially expressed genes across aging and SARS-CoV-2, based on the sum of
their ranks with log2-fold changes for each gene.
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Figure 3: Mining FDA approved drugs by correlating disease and drug signatures using an overparam-
eterized autoencoder embedding. (a) Gene expression (log2 RPKM +1) of A549-ACE2 cells infected
with SARS-CoV-2 versus normal A549-ACE2 cells with genes collected as part of the CMap study using
L1000 reduced representation expression profiling method highlighted as stars, showing that L1000 genes
significantly overlap with SARS-CoV-2 associated genes (p-value=7.94× 10−16, Fisher’s exact test). (b)
Signature of SARS-CoV-2 infection on A549 and A549-ACE2 cells visualized using the first two princi-
pal components based on RNA-seq data from [23]. Signature of SARS-CoV-2 infection is aligned across
normal A549 and A549-ACE2 cells as well as across different levels of infection. (c) Comparison of the
signatures of a selection of 13 representative FDA approved drugs as compared to the signature of SARS-
CoV-2 infection based on A549-ACE2 cells visualized using the first two principal components. Drugs
whose signatures maximally align with the direction from SARS-CoV-2 infection to normal are consid-
ered candidates for treatment. As expected, drugs have varying signatures of varying magnitudes. (d)
Correlation between drug signatures in A549 and MCF7 cells when using the original L1000 expression
space versus the embedding obtained from an overparameterized autoencoder. The overparameterized
autoencoder aligns the drug signatures in A549 and MCF7 cells by shifting the correlations towards -1 or
1 while maintaining the sign of the correlation in the original space. (e) Histogram of correlations between
cell types for a given drug using original L1000 gene expression vectors, overparameterized autoencoder
embedding, top 100 principal components, and top 3 principal components. The overparameterized au-
toencoder achieves about the same alignment of drug signatures as using the top 3 principal components,
while at the same time faithfully reconstructing the data (10−7 training error). (f) A list of drugs whose
signatures maximally align with the direction from SARS-CoV-2 infection to normal in A549-ACE2 cells
(MOI 2) with respect to correlations using the overparameterized autoencoder embedding, the original
L1000 gene expression space, and the top 100 principal components.
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Figure 4: Drug target discovery via Steiner tree analysis to identify putative molecular pathways linking
differentially expressed genes in SARS-Cov-2 infection and aging. (a) The general procedure takes as
input a list of genes of interest (terminal nodes) with prizes indicating their respective importance, a
protein-protein interaction (PPI) network with edge cost/confidence information (e.g. from IRefIndex
v14 [42]), and a list of drugs of interest along with their protein targets and available affinity constants
(e.g. from DrugCentral [44, 45]). In this study we consider 181 terminal nodes (of which 162 are present
in the IREF network) corresponding to genes differentially expressed in SARS-CoV-2 infection and aging
from Figure 2 that are either up-regulated in both SARS-Cov-2 infection and aging or down-regulated
in both SARS-Cov-2 infection and aging. The prize of a terminal node equals the absolute value of
its log2-fold change in SARS-Cov-2-infected A549-ACE2 cells versus normal A549-ACE2 cells based on
the data from [23]. Terminals and PPI data are processed using OmicsIntegrator2 [30] to output the
disease interactome, i.e., the subnetwork induced by a Steiner tree, with drug targets indicated by green
diamonds and terminal nodes colored according to their prizes. (b) Interactome obtained using this
procedure. Genes are grouped by general function and marked with a cross if known to interact with
SARS-Cov-2 proteins based on data from [6]. (c) 2-Nearest-Neighborhoods of nodes of interest (denoted
by a red hexagon) in the interactome. A threshold was applied on the edge confidence to improve
readability. Proteins known to interact with SARS-Cov-2 are denoted by blue squares, drug targets are
denoted as green diamonds, terminal nodes are colored according to their log2-fold change in SARS-Cov-
2-infected A549-ACE2 cells versus normal A549-ACE2 cells, Steiner nodes appear in grey. (d) Table
of drug targets and corresponding drugs in the interactome. Selected drugs are FDA approved, high
affinity (at least one of the activity constants Ki, Kd, IC50 or EC50 is below 10µM), and match the
SARS-Cov-2 signature well (correlation > 0.86). The affinity column displays − log10(activity). Protein
name corresponding to each gene is included.
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Figure 5: Causal mechanism discovery of potential drug targets. (a) In an undirected PPI network
(left), edge directions for a particular drug target (green diamond) are unknown. Establishing causal
directions is important since it is of interest to avoid drug targets that do not have many downstream
nodes in the disease interactome (middle) and instead choose drug targets that have a causal effect on
many downstream nodes in the disease interactome (right). (b) Causal network underlying the combined
SARS-CoV-2 and aging interactome in A549 cells with gene targets of selected drugs in boxes (largest
connected component shown). (c) Causal subnetwork of A549 cells corresponding to nodes within 5
nearest neighbors of RIPK1. The node color corresponds to the log2-fold change of A549-ACE2 with
versus without SARS-CoV-2. (d) Heatmap of log2-fold change of genes that are downstream of RIPK1.
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Supplementary Figures
Supplementary Fig. S1: (a) Gene expression of A549-ACE2 cells with and without SARS-CoV-2 in-
fection, with differentially expressed genes in red. (b) Gene expression of A549 cells with and without
SARS-CoV-2 infection, with differentially expressed genes in purple. (c) Gene expression of A549 cells
with and without ACE2 receptor, with differentially expressed genes in green. (d) Top 10 gene ontology
terms associated with differentially expressed genes between A549-ACE2 cells with and without SARS-
CoV-2 infection . (e) Top 10 gene ontology terms associated with differentially expressed genes between
A549 cells with and without SARS-CoV-2 infection. (f) Top 10 gene ontology terms associated with
differentially expressed genes between A549 cells with and without ACE2 receptor. All gene ontology
terms have adjusted p-value < 0.05.
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Supplementary Fig. S2: (a) Top 10 gene ontology terms associated with aging. (b) Venn diagram
showing significant overlap between aging associated genes considering different definitions of older,
specifically just individuals in the oldest category (70-79) or individuals that are 60-79.
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Supplementary Fig. S3: (a) Heatmap of log2-fold changes of differentially expressed genes shared by
SARS-CoV-2 and aging with gene names. (b) 2D histogram of the number of genes having a certain
rank in aging and SARS-CoV-2 datasets.
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Supplementary Fig. S4: (a) UMAP of control and perturbations across all cell types in CMap. The
effect of a perturbation on a given cell type is small relative to the differences between cell types. (b)
Principal component analysis highlighting batch effects for the control samples of the A549 cell line
from CMap. K-means clustering by gene expression vector is used to identify and remove batch effects
(represented as red and blue clusters).
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Num.
Hidden 
Units
Num. 
Hidden 
Layers
Nonlinearity Optimizer, LR Initialization Seed Used Training Loss Test Loss
1024 1 Leaky ReLU Adam, 1e-4 PyTorch
Default
17 7.3 x 10^-7 1.1 x 10^-6
100 1 Leaky ReLU Adam, 1e-4 PyTorch
Default
17 2.8 x 10^-3 2.8 x 10^-3
1024 1 CosID Adam, 1e-4 PyTorch
Default
17 6.4 x 10^-6 6.5 x 10^-6
Over-parameterized Autoencoder Under-parameterized Autoencoder
b
Supplementary Fig. S5: Overview of autoencoder architectures, optimization methods and hyperpa-
rameter settings considered. (a) Diagram representing an overparameterized autoencoder. While this
autoencoder is capable of learning the identity function, training leads to a solution that better aligns
drug signatures across cell types in the latent space. (b) Diagram representing an underparameterized
autoencoder. While this architecture is most commonly used in practice, it does not align drug signatures
as well in the latent space as its overparameterized counterpart; see Supplementary Fig. S7. (c) Details
on the width, depth, nonlinearity, optimization method, learning rate, random seed, training loss and
test loss for all architectures considered in this work.
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a b Under-parameterized Autoencoder Over-parameterized AutoencoderPCA (100 PCs)PCA (2 PCs) c d
Supplementary Fig. S6: Receiver operating characteristic (ROC) curves for the agreement in classi-
fication between gene expression vectors and reconstructed gene expression vectors obtained using an
embedding given by the first 2 principle components in (a), the first 100 principle components in (b), an
underparameterized autoencoder in (c), and an overparameterized autoencoder in (d). While a logistic
regression model trained to classify between 831 A549 control samples and 32893 A549 perturbation
samples shows differences in predictions on original gene expression vectors versus underparameterized
autoencoder reconstructions and reconstructions from the top 2 or 100 principal component, the overpa-
rameterized embedding allows near perfect reconstruction of the original gene expression vectors with no
difference in predictions between using overparameterized embeddings for gene expression vectors and
original gene expression vectors.
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Supplementary Fig. S7: Comparison of drug signature alignment between A549 and MCF7 (top) and
A549 and HCC515 (bottom) cell types upon using an embedding verus the original space. Embeddings
provided include (from left to right) top 2 PCs, top 100 PCs, underparameterized leaky ReLU autoen-
coder, overparameterized cosid autoencoder, overparameterized leaky ReLU autoencoder. Embeddings
from the overparameterized autoencoder with leaky ReLU activation better align drug signatures be-
tween these two pairs of cell types than any other embedding considered while still providing near perfect
reconstruction of the original data.
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min = 0.98
max  = 6.22
mean = 1.46
sd = 0.56
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Supplementary Fig. S8: Terminal node selection for prize-collecting Steiner forest analysis. Terminal
genes include 162 genes present in the IREF interactome that are either upregulated in both SARS-Cov-2
infection and aging or downregulated in both SARS-Cov-2 infection and aging. Each terminal gene is
prized with its absolute log2-fold change between SARS-Cov-2 infected A549-ACE2 cells and normal
A549-ACE2 cells. (a) Histogram of prizes for terminal genes along with descriptive statistics. (b) Table
of 75 terminal genes upregulated in both SARS-Cov-2 infection and aging (left) and table of 87 terminal
genes downregulated in both SARS-Cov-2 infection and aging, along with prize and log2 fold change
information.
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Supplementary Fig. S9: Parameter selection via sensitivity analysis for prize-collecting Steiner forest
analysis. (a1) Boxplot of penalized edge costs in the IREF interactome for different values of g. The
distribution of penalized edge costs are very similar for g = −∞ and g = 0. For these values of g, the
maximum penalized edge cost is upper bounded by 1. (a2) Histogram of shortest path cost between
any two terminals in the IREF interactome for g = 0, along with descriptive statistics. (b) Range of
parameters g, w and b used in sensitivity analysis. Red values indicate a stable range for the interactome
obtained with the prize-collecting Steiner forest algorithm. We retain g = 0, w = 1.4 and b = 40
for our subsequent analysis. (c1-3) Heatmaps of the matrix M indexed for different types of selected
nodes: all nodes (c1), terminal nodes (c2) and SARS-Cov-2 interaction partners (c3). Each row/column
corresponds to a prize-collecting Steiner forest obtained from a given set of parameters (g = 0, w, b). A
stability region for the prize-collection Steiner forest solution appears for g = 0, w ≥ 1.2 and b ∈ [5, 50].
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Supplementary Fig. S10: Interactome obtained from the prize-collecting Steiner forest algorithm (with
parameters g = 0, w = 1.4, b = 40) using the terminal gene list from Supplementary Fig. S8. The
interactome contains 1,003 edges between 252 genes, five of which are known SARS-Cov-2 interaction
partners (EXOSC5, FOXRED2, LOX, RBX1, RIPK1). Genes in the interactome are grouped by general
process.
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Supplementary Fig. S11: Selection of the prize p for non-terminal SARS-Cov-2 interaction partners (all
but EXOSC5, FOXRED2 and LOX) via sensitivity analysis. (a) Number of SARS-Cov-2 interaction
partners collected in the interactome obtained from the prize-collecting Steiner forest algorithm for
different values of p ranging from 0 to 0.02. For p > 0.02, all known SARS-Cov-2 interaction partners
present in the IREF network are collected in the final interactome. A stability region appears for
p ∈ [4 · 10−4, 10−3] with 7 SARS-Cov-2 interaction partners collected. (b-c) Heatmaps of the matrix M
indexed for different types of selected nodes: all nodes (b), and SARS-Cov-2 interaction partners (c).
Each row/column corresponds to a prize-collecting Steiner forest obtained from a given set of parameters
(g = 0, w = 1.4, b = 40, p). A stability region for the prize-collection Steiner forest solution appears for
g = 0, w = 1.4 and b = 40 and p ∈ [7 · 10−4, 10−3]. We retain g = 0, w = 1.4, b = 40 and p = 8 · 10−4
for our subsequent analysis.
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Supplementary Fig. S12: Interactome obtained from the prize-collecting Steiner forest algorithm (with
parameters g = 0, w = 1.4, b = 40) using the terminal gene list from Supplementary Fig. S8 augmented
with all other SARS-Cov-2 interaction partners prized with p = 8 · 10−4. The interactome contains
1,090 edges between 254 genes, seven of which being known SARS-Cov-2 interaction partners (EXOSC5,
FOXRED2, LOX, RBX1, RIPK1, CUL2, HDAC2). Genes in the interactome are grouped by general
function.
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Supplementary Fig. S13: 2-Nearest-Neighborhoods of nodes of interest (denoted by a red hexagon) in
the interactome of Supplementary Fig. S12 (parameters g = 0, w = 1.4, b = 40, p = 8·10−4). A threshold
was applied on the edge confidence to improve legibility. Proteins known to interact with SARS-Cov-2
are denoted as blue squares, drug targets are denoted as green diamonds, terminal nodes are colored
according to log2-fold change in SARS-Cov-2-infected A549-ACE2 cells versus normal A549-ACE2 cells,
Steiner nodes appear in grey.
35
Supplementary Fig. S14: Drug target discovery via prize-collecting Steiner forest analysis to identify
putative molecular pathways linking differentially expressed genes in SARS-Cov-2 infection without tak-
ing into account age-related differential expression. (a) The general procedure to obtain the interactome
is identical to the one described in Fig. 4a, with a different terminal gene list. (a) Terminal nodes and
histogram of prize distribution. We consider 169 terminal nodes corresponding to genes differentially
expressed in SARS-CoV-2 infection after removing the effect of the ACE2 receptor. Only 11 of these 169
genes belong to the terminal list used in Fig. 4. The prize of a terminal node equals the absolute value of
its log2-fold change in SARS-Cov-2-infected A549-ACE2 cells versus normal A549-ACE2 cells based on
data from [23]. (b) Sensitivity analysis to choose the parameters w and b for the prize-collecting Steiner
forest algorithm. We select g = 0, w = 1.4 and b = 40 corresponding to a robust solution for moderate
changes in the parameters. (c) Interactome obtained using the prize-collecting Steiner forest algorithm.
Genes are grouped by general function and marked with a cross if known to interact with SARS-Cov-2
proteins based on data from [6]. (d) 2-Nearest-Neighborhoods of nodes of interest (denoted by a red
hexagon) in the interactome. A threshold was applied on the edge confidence to improve legibility. Pro-
teins known to interact with SARS-Cov-2 are denoted as blue squares, drug targets are denoted as green
diamonds, terminal nodes are colored according to log2-fold change in SARS-Cov-2-infected A549-ACE2
cells versus normal A549-ACE2 cells, Steiner nodes appear in grey. (e) Table of drug targets in the
interactome with the corresponding drugs. Selected drugs are FDA approved, high affinity (at least one
of the activity constants Ki, Kd, IC50 or EC50 is below 10µM), and match the SARS-Cov-2 signature
well (correlation > 0.86). The affinity column displays − log10(activity). Protein name corresponding to
each gene is included.
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Supplementary Fig. S15: (a) Matrix Q of estimated effects of interventions (columns) on measured genes
(rows) in A549 cells from CMap gene knockout and overexpression data with Qij = 1 representing that
perturbing gene j effects gene i and hence that gene i is downstream of gene j. (b) ROC curve evaluating
causal structure discovery methods GSP, PC and GES for predicting the effects of interventions in A549
cells. The performance of each algorithm is measured by sampling random causal graphs and measuring
number of true positives and false positives. GSP performs significantly above random guessing with
p-value of 0.0177, while PC achieves p-value of 0.0694 and GES a p-value of 0.5867. The grey line
represents a random guessing baseline (not used for computation of p-value) based on the number of
ground truth positives and negatives, calculated from Q and scaled to extend from (0, 0) to span the
entirety of the plot.
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Supplementary Fig. S16: (a) Causal network corresponding to A549 cells. (b) Causal network corre-
sponding to AT2 cells. (c) Causal network corresponding to A549 cells learned using PPI interactome
obtained without considering age-associated genes as a prior. All non-singleton nodes are shown, gene
targets of drugs selected via our computational drug repurposing pipeline are in boxes and the node
color corresponds to the log2-fold change of A549-ACE2 with versus without SARS-CoV-2.
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Supplementary Tables
Drug name
% differentially expressed
nodes downstream (A549)
% nodes downstream
(A549 no age)
% nodes downstream
(AT2)
afatinib 98.51 0.00 83.93
axitinib 98.51 0.85 83.93
bosutinib 98.51 0.00 83.93
dasatinib 98.51 0.00 83.33
erlotinib 98.51 0.00 83.33
imatinib 98.51 0.00 83.93
pazopanib 98.51 0.85 83.93
ruxolitinib 98.51 0.00 83.33
sorafenib 97.01 0.00 0.60
sunitinib 98.51 0.85 83.93
tofacitinib 1.49 0.00 0.00
belinostat 98.51 94.92 83.33
vorinostat 98.51 94.92 83.33
formoterol 98.51 94.92 83.33
primaquine 98.51 94.92 83.33
vardenafil 0.00 0.00 0.00
milrinone 0.00 0.00 0.00
docetaxel 98.51 0.00 83.33
Table S1: Percentage of nodes in the largest connected component of the corresponding causal graph
that are targeted by each drug. For A549 cells, only genes that are associated with SARS-CoV-2 and
aging are considered.
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Supplementary Datasets
Dataset 1: Correlation of each drug applied to A549, MCF7 and HCC515 cells measured in CMap [2] with
the direction from SARS-CoV-2 infection to normal in A549-ACE2 cells, calculated using autoencoder
embedding, original space and top 100 principal components.
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